Key Highlights
- The 31 July decline followed a 27.3% post-earnings surge on 30 July; the stock is near 52-week highs, not breaking down.
- Growth has shifted decisively to oncology, with the Korlym Franchise up roughly 7% year over year while total Revenue rose 32%.
- The forward P/E near 28.5 depends on consensus Earnings rising from $0.78 in 2026 to $3.65 in 2027, which assumes SG& Amp ;A growth moderates.
- Corcept Therapeutics shares slipped 2.7% on Friday 31 July, closing at $115.17.
A 27% jump, then a step back
Corcept Therapeutics ( Nasdaq :CORT) shares slipped 2.7% on Friday 31 July, closing at $115.17. That decline says far less about the Business than the session before it. On 30 July, the day after second-quarter results landed, the stock climbed 27.3% on 4.5 million shares, roughly four times the recent daily average, making Friday's move a routine give-back after one of the sharpest single-day gains in the company's history. (Data providers disagree on Friday's print: aggregated market data's summary page listed a $114.49 close and a 3.2% fall, against $115.17 and 2.7% in its own daily history table.)
The catalyst was Lifyorli (relacorilant), approved by the FDA alongside nab-paclitaxel for platinum-resistant ovarian cancer. In its first full quarter it produced $47.6 million of revenue, and management lifted 2026 guidance to $1.1–$1.2 billion, up from $950 million–$1.05 billion in April and an initial $900 million–$1.0 billion in February.
What the tape has been pricing
Over the past 12 months the stock has gained about 64%, but the path has been violent. The 52-week range runs from $28.66 to $122.21, and those extremes map onto two events: a Complete Response Letter on the Cushing's syndrome application received at last closing, and the oncology approval and ramp that followed. Market Capitalization is $12.38 billion against an Enterprise value of $11.76 billion. Short interest of 8.7% of shares outstanding helps explain the violence of the post-earnings move.
Two franchises, moving in opposite directions
Korlym (mifepristone) and its authorized generic generated $208.6 million in the quarter. Set against total revenue of $194.4 million in the second quarter of 2025, all of it hypercortisolism at the time, that implies roughly 7% growth for the legacy franchise, far below the 32% consolidated rate.
Pressure on the endocrine base is not hypothetical. The US Court of Appeals for the Federal Circuit affirmed a December 2023 New Jersey district court verdict that Teva's generic mifepristone does not infringe two Corcept patents covering safe co-administration with CYP3A4 inhibitors, clearing Teva to market its copy. Chief executive Joseph Belanoff said the company was "considering the best way to pursue judicial review of this decision." Corcept already sells an authorized generic itself, which cushions unit loss but not price.
The quarter: growth bought with spending
Second-quarter revenue reached $256.1 million, up 32% year over year, with Net Income of $43.0 million and diluted earnings of $0.36 against $0.29. That marked a return to profit after a first quarter that swung to a $31.8 million loss, or $0.30 per share, on revenue of $164.9 million.
The swing Factor is commercial Investment . Operating expenses hit $214.8 million in the quarter versus $167.8 million a year earlier. Across the first half, selling, general and administrative costs reached $302.3 million and Research and Development $120.2 million, against half-year revenue of $421.1 million and net income of just $11.2 million. Gross Margin is essentially 98%, so the whole earnings question is Operating Leverage on that sales build. Cash and investments stood at $544.6 million at 30 June with negligible Debt , though no stock was repurchased in the first half after $130.5 million of Buybacks a year earlier.
Cushing's: a December rerun
The Complete Response Letter is the unresolved item. The FDA acknowledged that the pivotal GRACE Phase 3 trial met its primary endpoint and that the GRADIENT study was supportive, yet concluded it could not reach a favorable benefit-risk assessment without additional evidence of effectiveness. Corcept resubmitted the application after supplying further analyses of the existing dataset; the agency's action date is.
Approval matters commercially because Corcept has spent years enlarging the diagnosed population. The CATALYST study screened 1,057 patients with difficult-to-control type 2 diabetes and found 24% had hypercortisolism on a 1-mg dexamethasone suppression test. In the randomized phase, 136 patients received Korlym or placebo for 24 weeks; the treated group saw HbA1c fall 1.3 percentage points (p<0.001) and weight drop 5.1 kg. New data at ADA in June, covering 71 participants also taking a GLP-1 or tirzepatide, showed a 1.7-point HbA1c reduction and 6.1 kg of weight loss. That larger pool is worth far more if the drug capturing it is proprietary rather than genericized.
Competition in that niche is real. Recordati's Isturisa (osilodrostat) blocks cortisol synthesis and is approved for hypercortisolemia in Cushing's patients ineligible for or not cured by surgery. Xeris Biopharma's Recorlev reported $50 million of net revenue in the first quarter of 2026, up 95% year over year.
The case for paying up
ROSELLA gave Corcept the strongest dataset in its history. Across 381 randomized patients, relacorilant plus nab-paclitaxel delivered median overall survival of 16.0 months versus 11.9 months (hazard ratio 0.65, p=0.0004) and a 30% reduction in progression risk (HR 0.70, p=0.008). There is no biomarker requirement, the regimen entered NCCN guidelines as a preferred option in April, more than 1,300 patients have started therapy, and a European decision is expected by year-end. Cortisol modulation has now been validated outside endocrinology, which is the argument for treating the dazucorilant, MASH and prostate cancer programs as Options rather than science projects.
Where the skeptics stand
Against that, the December action date is a genuine binary given the agency has already refused once, and the legacy franchise is growing at single digits into an open generic pathway. The pipeline's headline survival signals also come with caveats: the DAZALS Phase 2 study in ALS missed its primary ALSFRS-R endpoint even as 300 mg dazucorilant showed an 87% reduction in two-year mortality risk (HR 0.13, p<0.0001), and its Phase 3 has slipped to early 2027 from earlier guidance of a 2026 start. Analyst dispersion says the same, four analysts tracked by S&P Global average a $117.75 target, with a low of $50 and a high of $165.
What the multiple assumes
Trailing earnings are not a usable yardstick: the P/E of 252 reflects a first-half launch-spending trough, not run-rate Economics . The forward multiple of roughly 28.5 times is the fairer number, and it rests on a steep ramp, consensus earnings of $0.78 for 2026 against $3.65 for 2027. On sales the stock trades near 14.8 times trailing revenue and 14.2 times enterprise value to revenue, with free Cash Flow of $107 million producing a 0.9% Yield . Investors are paying for 2027, which requires the oncology launch to compound and the SG&A line to stop outrunning revenue.
The balance into year-end
Two dated events, the European oncology decision and the 17 December FDA action, will determine whether relacorilant becomes a two-indication franchise or a single oncology drug attached to an eroding endocrine base. Third-quarter results will show whether the Lifyorli ramp is durable and whether operating leverage has begun to appear.
Upcoming Catalysts
- FDA action date for relacorilant in Cushing's syndrome. A second refusal after the Complete Response Letter would strand the CATALYST prevalence strategy.
- European decision on relacorilant in platinum-resistant ovarian cancer, expected by year-end 2026. Opens the largest ex-US oncology market.
- Third-quarter 2026 results, expected late October 2026. First read on Lifyorli's second full quarter and on operating leverage.
- MONARCH Phase 2b in MASH, results expected by year-end 2026. Tests cortisol modulation in a mass-market indication.
- Dazucorilant Phase 3 in ALS, start guided to early 2027. Confirmation of the survival signal seen in DAZALS.
Principal Risks
- Regulatory repeat. The FDA has already declined the Cushing's application once, citing insufficient evidence of effectiveness despite GRACE meeting its endpoint; the resubmission adds analyses, not new trials.
- Generic mifepristone. The Federal Circuit cleared Teva to market a generic Korlym in February 2026, exposing roughly four-fifths of current revenue to price erosion.
- Cost base. First-half SG&A of $302.3 million on $421.1 million of revenue left only $11.2 million of net income; the 2027 earnings ramp fails if that spending does not level off.
- Launch concentration. With no biomarker requirement but a defined third- and fourth-line population, Lifyorli's addressable pool is finite, and second-quarter uptake is too short a record to extrapolate.
- Thin coverage and high short interest. Four tracked analysts with targets from $50 to $165, and 8.7% short interest, make the shares prone to outsized moves on single data points.
Conclusion
The 31 July decline followed a 27.3% post-earnings surge on 30 July; the stock is near 52-week highs, not breaking down. Set against that: The FDA has already declined the Cushing's application once, citing insufficient evidence of effectiveness despite GRACE meeting its endpoint; the resubmission adds analyses, not new trials. The next real test: A second refusal after the Complete Response Letter would strand the CATALYST prevalence strategy.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...